More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$716729433
EPS
0.16
P/E ratio
--
Price to sales
1.26
Dividend yield
--
Beta
0.793346
Previous close
$8.58
Today's open
$8.58
Day's range
$8.51 - $8.78
52 week range
$5.81 - $11.25
show more
CEO
Robert E. Claypoole
Employees
930
Headquarters
Durham, NC
Exchange
Nasdaq Global Select
Shares outstanding
82763214
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
GlobeNewsWire • 3 hours ago

Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Seeking Alpha • Jan 14, 2026

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET).
GlobeNewsWire • Jan 6, 2026

HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders.
PRNewsWire • Dec 5, 2025

Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3, 2025, at 10:10 a.m. ET.
GlobeNewsWire • Nov 25, 2025

Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript
Bioventus Inc. ( BVS ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton - Senior VP & CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Presentation Operator Good day, and welcome to the Bioventus Inc. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Seeking Alpha • Nov 4, 2025

Bioventus Reports Third Quarter Financial Results
DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 27, 2025.
GlobeNewsWire • Nov 4, 2025

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday, November 4, 2025.
GlobeNewsWire • Oct 28, 2025

Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders. If you currently own Bioventus stock and acquired shares on or before February 11, 2021, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn mor.
Business Wire • Oct 22, 2025

Bioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Bioventus Inc. (NASDAQ:BVS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Mark Singleton - Senior VP & CFO Presentation Unknown Analyst Thanks, everyone, for joining us. Before we begin, just the disclaimer.
Seeking Alpha • Sep 10, 2025

¹ Disclosures

Open an M1 investment account to buy and sell Bioventus Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.